Newswire (Published: Monday, May 13, 2019, Received: Monday, May 13, 2019, 6:09:05 PM CDT)

Word Count: 489

2019 MAY 13 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Drug Daily -- Data detailed on Oncology - Prostate Cancer have been presented. According to news originating from Columbia, Missouri, by NewsRx correspondents, research stated, “The objective of this research was to estimate the dose distribution delivered by radioactive gold nanoparticles (AuNPs or AuNPs) to the tumor inside the human prostate as well as to normal tissues surrounding the tumor using the Monte-Carlo N-Particle code (MCNP-6.1.1 code). Radioactive gold nanoparticles are emerging as promising agents for cancer therapy and are being investigated to treat prostate cancer in animals.”

Funders for this research include Ministry of Higher Education and Scientific ResearchMinistry of Higher Education and Scientific Research, Nuclear Science and Engineering Institute, U.S. Department of EducationU.S. Department of Education, U.S. Nuclear Regulatory CommissionU.S. Nuclear Regulatory Commission.

Our news journalists obtained a quote from the research from the University of Missouri, “In order to use them as a new therapeutic modality to treat human prostate cancer, accurate radiation dosimetry simulations are required to estimate the energy deposition in the tumor and surrounding tissue and to establish the course of therapy for the patient. A simple geometrical model of a human prostate was used, and the dose deposited by AuNPs or AuNPs to the tumor within the prostate as well as to the healthy tissue surrounding the prostate was calculated using the MCNP code. Water and A-150 TEP phantoms were used to simulate the soft and tumor tissues. The results showed that the dose due to AuNPs or AuNPs, which are distributed homogenously in the tumor, had a maximal value in the tumor region and then rapidly decreased toward the prostate-tumor interface and surrounding organs. However, the dose deposited by Au is significantly higher than the dose deposited by Au in the tumor region as well as normal tissues.”

According to the news editors, the research concluded: “According to the MCNP results, AuNPs are a promising modality to treat prostate cancer and other cancers and AuNPs could be used for imaging purposes.”

For more information on this research see: Estimation of tumor and local tissue dose in gold nanoparticles radiotherapy for prostate cancer. Reports of Practical Oncology & Radiotherapy, 2019;24(3):288-293. (Elsevier - www.elsevier.com; Reports of Practical Oncology & Radiotherapy - http://www.journals.elsevier.com/reports-of-practical-oncology-and-radiotherapy/)

The news correspondents report that additional information may be obtained from A.Y. Al-Yasiri, Nuclear Science and Engineering Institute, University of Missouri, Columbia, MO, United States. Additional authors for this research include N.E. White, K.V. Katti and S.K Loyalka.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.rpor.2019.02.006. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

University of Missouri

Industries

Technology
      Nanotechnology

Places

North America
United States
Americas
Missouri
Columbia

Subjects

Science and Technology
      Scientific Research
      Sciences
            Physical Sciences
                  Physics
      Technology
            Nanotechnology and Quantum Technology
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies
            Radiation Therapy